FluoGuide A/S provided an update on the clinical timelines for the ongoing clinical phase IIb trial of FG001 in patients with aggressive brain cancer (high grade glioma) undergoing surgery. Based on latest estimate, the Company expects the last patient in the ongoing clinical trial of FG001 in patients with aggressive brain cancer to be enrolled during the summer 2023. The topline result will be presented approx.

8 weeks after last patient is enrolled. The 8 weeks are needed for the histopathologists to analyse the biopsies and the radiologists to analyse the MRI scans. The analysis of the biopsies and MRI scans is blinded and can therefore first be initiated after the last patient has been enrolled.

The topline result was previously estimated to first half 2023. The guidance for the topline results of the lung and head & neck trials remains unchanged.